Mentice

14,80 SEK

0,00 %

Mindre end 1K følgere

MNTC

First North Stockholm

Medical Equipment & Services

Health Care

Oversigt

Finansielt overblik og estimater

Ejerskab

Investorkonsensus

0,00 %

+27,59 %

+8,42 %

-27,96 %

-41,24 %

-40,78 %

-58,38 %

-82,35 %

-77,83 %

Mentice operates in the medical technology sector. The company develops medical instruments for endovascular simulation and for training sessions in surgery. The programs are developed for use in educational purposes among hospitals and institutes. The largest operations are found in North America and Europe. In addition to the main business, opportunities for leasing, support, and technical service are offered. The headquarters are located in Gothenburg.

Markedsværdi

416,26 mio. SEK

Aktieomsætning

4,39 t SEK

Omsætning

290,33 mio.

EBIT %

-4,27 %

P/E

-

Udbytteafkast, %

-

Omsætning og EBIT-margin

Omsætning mio.

EBIT-% (adj.)

EPS og udbytte

EPS (adj.)

Udbytte %

Finanskalender

26.2

2026

Årsrapport '25

7.5

2026

Delårsrapport Q1'26

26.5

2026

Generalforsamling '26

Alle

Selskabsmeddelelser

ViserAlle indholdstyper

Pressemeddelelse7.11.2025, 06.32

DNB Carnegie Access: Mentice: Starting to show strong operating leverage – Q3 review

Pressemeddelelse6.11.2025, 07.45

DNB Carnegie Access: Mentice: Shows strong operational leverage – Q3 initial take

Selskabsmeddelelse6.11.2025, 06.00

Mentice publishes the company’s interim report for the period July – September 2025

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto

Følgere og notifikationer om fulgte virksomheder

Analytikerkommentarer og anbefalinger

Værktøj til at sammenligne aktier og andre populære værktøjer

Selskabsmeddelelse23.10.2025, 13.30

Nomination Committee has been appointed for Mentice AB (publ) Annual General Meeting 2026

Pressemeddelelse23.10.2025, 07.00

Mentice to Present Q3 2025 Interim Report via Webcast

Pressemeddelelse3.10.2025, 06.53

DNB Carnegie Access: Mentice: Cost-control focus – Q3 preview

Pressemeddelelse21.8.2025, 06.15

Mentice receives approximately SEK 31.95 million through oversubscribed rights issue

Pressemeddelelse4.8.2025, 13.00

Mentice publishes information document regarding rights issue

Pressemeddelelse1.8.2025, 11.00

Mentice receives an additional Subscription Commitment of 3.4 MSEK in the upcoming Rights Issue

Pressemeddelelse25.7.2025, 07.53

DNB Carnegie Access: Mentice: Shows resilience in adj. EBITDA – Q2 review

Pressemeddelelse24.7.2025, 11.05

DNB Carnegie Access: Mentice: Recording from earnings call Q2 (25)

Pressemeddelelse24.7.2025, 07.07

DNB Carnegie Access: Mentice: FX and comparables tougher than feared – Q2 initial take

Selskabsmeddelelse24.7.2025, 06.00

Mentice resolves on a rights issue of approximately SEK 31.95 million

Selskabsmeddelelse24.7.2025, 05.00

Mentice publishes the company’s interim report for the period April–June 2025

Pressemeddelelse11.7.2025, 14.00

Mentice AB Announces Consolidation of Physical Simulation Operations to Strengthen Long-Term Efficiency and Global Service Delivery

Pressemeddelelse10.7.2025, 06.00

Mentice to Present Q2 2025 Interim Report via Webcast

Pressemeddelelse18.6.2025, 11.00

BioStock: Mentice announces workforce realignment and plans capital raise

Pressemeddelelse18.6.2025, 08.45

DNB Carnegie Access: Mentice: Cost-cutting programme highlights short-term challenges

Selskabsmeddelelse16.6.2025, 13.58

Mentice AB announces the intent for a strategic workforce realignment to enhance focus and operational efficiency and the intent for a rights issue of max 10% of the share capital

Selskabsmeddelelse27.5.2025, 14.00

Communique from annual general meeting in Mentice AB

Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.